reason report
recap pipelin track
bottom line report busi result provid
pipelin updat line expect updat
call minor includ confirm initi phase
data american societi hematolog
addit clinic studi
plan provid call would continu
focu acut myeloid leukemia aml abstract
releas tomorrow estimate expect
data compar earli phase data bispecif
includ program op rhhby/genentech
also provid updat data overal continu view
leader promis bispecif space view compani plug-
and-play antibodi platform import long-term valu driver
potenti sourc busi develop opportun futur
compani enter numer technolog licens agreement
repres valid platform near-term cash flow
compani view well-posit execut long-
term strategi strong manag team financi posit
upcom catalyst mileston includ initi phase data
b-cell malign
ind applic
bispecif partner genentech initi phase data
neuroendocrin gastrointestin
stromal tumor gist initi data tumor
microenviron tme bispecif platform data
phase studi advanc solid
tumor initi addit clinic studi
continu guid toward cash suffici fund
oper beyond chang vs previou end
cash cash equival expect end
approxim cash equival vs
lower pt previous lower
estim given limit visibl potenti partnership
develop path forward
year price history/av daili volume mil
compani inform svb leerink llc research
revenu mm dilut gaap ep
pleas refer page import disclosur price chart analyst certif
clinical-stag biotechnolog compani develop engin antibodi treat
autoimmun allerg diseas cancer indic plug-and-play
antibodi platform gener deep pipelin consist advanc stage proprietari
program earli stage partner proprietari bispecif antibodi deep
pipelin earli stage bispecif antibodi program expect multipl clinic
readout view bispecif antibodi promis drug class view
bispecif platform import long-term valu driver compani potenti
sourc busi develop opportun futur addit enter
numer technolog licens agreement repres valid platform well
near-term cash flow compani view well-posit execut long-
term strategi strong manag team financi posit
price target base blend revenu multipl analysi
dcf analysi assign valu probability-weight sale royalti
probabl success diseas probability-weight sale royalti
probabl success acut myeloid leukemia probability-weight sale
royalti probabl success lymphoma probability-weight
royalti probabl success multipl myeloma probability-weight
royalti probabl success complement-medi diseas
probability-weight royalti probabl success lymphoma use
discount rate termin growth rate
pipelin program face clinic regulatori develop risk well commerci
intellectu properti risk also face execut risk financi risk may
addit financ need turn cash flow posit
collabor licens revenu
loss settlement note
total incom expens
net deem contribut exchang sale prefer stock
net unreal loss gain market secur
net incom loss attribut common stockhold
pro-forma basic diulut share outstand
sti
svb leerink estim compani file
chang
oper
chang wc
invest
financ
svb leerink estim compani file
pipelin upcom event
approv launch us eu japan
initi addit studi
expect complet
svb leerink compani file
royalti sale npv mm
